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Abstract
Background and Aims: Acute liver failure (ALF) is a rare dis-
ease with potentially high mortality rates. We aimed to 
study the recent epidemiology of ALF in one of the Portu-
guese liver transplant (LT) regions. Methods: We assessed 
a retrospective cohort including 34 consecutive patients 
with ALF admitted to the intensive care unit (ICU) of Curry 
Cabral Hospital (Lisbon, Portugal) between October 2013 
and December 2016. Results: The median age (IQR) was 49 
(31–67) years, and 21 (62%) of the cohort were female. Non-
paracetamol etiologies were found in 29 patients (85%). On 
ICU admission, grade 3–4 hepatic encephalopathy devel-
oped in 10 patients (29%); invasive mechanical ventilation, 
vasopressors, and renal replacement therapy were required 
for 8 (24%), 7 (21%), and 5 (15%) of the patients, respec-
tively; the King’s College criteria (KCC) were fulfilled by 16 
patients (47%). Of the 15 (44%) nontransplanted patients, 
11 (73%) died during their hospital stay. Of the 19 (56%) 
transplanted patients, 4 (21%) died during their hospital 
stay. KCC were not associated with hospital mortality (p = 
0.97), but they were significantly associated with LT (p = 
0.008). Conclusions: In a Portuguese cohort of patients 
with ALF, non-paracetamol etiologies were predominant. 
Hospital mortality was much lower amongst transplanted 
patients. © 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
Epidemiologia da Falência Hepática Aguda de um 
Centro de Transplante Regional em Portugal
Palavras Chave
Falência hepática · Etiologia · Transplantação
Resumo
Introdução: A falência hepática aguda (ALF) é uma doen-
ça rara com potenciais altas taxas de mortalidade. Preten-
deu-se estudar a epidemiologia recente da ALF numa das 
regiões portuguesas de transplante hepático (LT). Mate-C.S., S.S., and M.V. share first authorship.
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riais e Métodos: Coorte retrospectivo incluindo 34 doen-
tes com ALF consecutivamente admitidos na Unidade  
de Cuidados Intensivos (ICU) do Hospital Curry Cabral  
(Lisboa, Portugal) entre Outubro de 2013 e Dezembro de 
2016. Resultados: A idade mediana foi 49 (31–67) anos e 
21 (62%) doentes eram do sexo feminino. As etiologias 
não-paracetamol ocorreram em 29 (85%) doentes. Na ad-
missão na ICU, a encefalopatia hepática grau 3–4 desen-
volveu-se em 10 (29%) doentes; a ventilação mecânica  
invasiva, os vasopressores e a técnica de substituição da 
função renal foram usados em 8 (24%), 7 (21%) e 5 (15%) 
doentes, respectivamente; os critérios King’s College Hos-
pital (KCC) foram cumpridos por 16 (47%) doentes. Entre 
os 15 (44%) doentes não transplantados, 11 (73%) mor-
reram durante a estadia hospitalar. Entre os 19 (56%) 
doentes transplantados, 4 (21%) morreram durante a es-
tadia hospitalar. Os KCC não se associaram com a mor-
talidade hospitalar (p = 0.97), mas associaram-se significa-
tivamente com o LT (p = 0.008). Conclusões: Num coorte 
de doentes com ALF português, as etiologias não-
paracetamol predominaram. A mortalidade hospitalar foi 
significativamente menor nos doentes transplantados.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Acute liver failure (ALF) is a rare life-threatening dis-
ease characterized by recent deterioration of liver func-
tion associated with coagulopathy and hepatic encepha-
lopathy (HE) without evidence of cirrhosis [1, 2]. In the 
absence of HE, this type of liver dysfunction is often de-
fined as acute liver injury (ALI).
The incidence of ALF in Europe has been reported as 
fewer than 10 cases per million people per year in devel-
oped countries [1]. Based on the European Liver Trans-
plant Registry, ALF has been the primary indication in 8% 
of all liver transplant (LT) procedures undergone be-
tween 1988 and 2009: 21% of them were due to viral in-
fection, 21% due to drug-induced liver injury (11% by 
paracetamol and 10% by other drugs), and 58% due to 
other causes or unknown etiology [2].
ALF etiologies vary worldwide: while in Eastern devel-
oping countries, viruses (mainly hepatitis A, B, or E) may 
account for up to 95% of all ALF cases, the Western de-
veloped countries have reported more heterogeneous 
causes of ALF [3, 4]. In the UK and North America, 
paracetamol overdosage has been the leading cause of 
ALF [5, 6]. In parts of Europe (e.g., Germany and Portu-
gal), the most common causes of ALF have been non-
paracetamol drug-induced liver injury, seronegative (in-
determinate) liver injury, and viruses (mostly hepatitis B) 
[7, 8].
ALF still portends high mortality rates, but these have 
been decreasing over time owing to improvements in 
critical care management and in emergent LT. Overall 
hospital survival increased from 17% in 1973–1978 to 
62% in 2004–2008 at a single center in the UK [3]. In a 
multicenter registry from the USA, in 1998–2010 ALF 
2-year survival has been reported as 92% for LT recipi-
ents, 90% for paracetamol-related spontaneous survivors, 
and 76% for non-paracetamol-related spontaneous sur-
vivors [9].
Taking into account the variations in ALF epidemiol-
ogy with geography worldwide, we sought to study the 
current ALF epidemiology in Lisbon, one of the LT re-
gions in Portugal.
Subjects and Methods
Design, Setting, and Participants
This was a retrospective cohort study including all consecutive 
adult patients (≥18 years) diagnosed with ALF admitted to a spe-
cialized intensive care unit (ICU) at Curry Cabral Hospital (Lis-
bon, Portugal) between October 2013 and December 2016. We 
started patient inclusion at this time point because the quality of 
the granular data recorded from then on was much better than be-
fore.
The inclusion criteria were the following: age ≥18 years, ALF, 
and first admission to the ICU in the follow-up period (last date 
available before June 2016). The exclusion criteria were the follow-
ing: alcoholic hepatitis or previous LT.
INR ≥1.5 + hepatic encephalopathy
(West Haven criteria) on admission to ICU
INR ≥1.5 + NH3 ≥100 μmol/L on admission to ICU
ALF criteria during follow-up
n = 27
n = 27 + 3 = 30
n = 30 + 4 = 34
Fig. 1. Selection of patients with acute liver failure (ALF) admitted 
to the intensive care unit (ICU).
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Given the observational character of the study, the local ethics 
committee waived the need for individual informed consent. The 
principles of the Declaration of Helsinki were respected through-
out the study development [10].
Definitions, Data Collection, and Endpoints
ALF was defined as: onset of liver dysfunction < 26 weeks with 
an INR ≥1.5 and any degree of HE (West Haven criteria) or NH3 
≥100 µmol/L in the absence of cirrhosis. ALI was defined as: onset 
of liver dysfunction < 26 weeks with an INR ≥1.5, no HE (West 
Haven criteria), and NH3 < 100 µmol/L in the absence of cirrhosis. 
Given that the West Haven criteria are often difficult to apply, es-
pecially to subclinical HE, we decided to use the arterial NH3 level 
(at least 2 times the normal level) to help define ALF-related HE 
[11].
The selection criteria for LT for patients with ALF at our center 
have been based on the King’s College criteria (KCC) [12]: for 
paracetamol-related ALF, (1) the single criterion of a serum pH 
< 7.30 or lactate > 3.0 mmol/L or (2) three of the following criteria: 
grade III–IV HE, an INR > 6.5, and serum creatinine > 3.4 mg/dL; 
for non-paracetamol-related ALF, (1) the single criterion of an 
INR > 6.5 or (2) three of the following criteria: age < 10 or > 40 years, 
time from jaundice to coma > 7 days, an INR > 3.5, serum bilirubin 
> 17 mg/dL, and/or an unfavorable etiology (drug-induced liver 
injury, Wilson disease, or seronegative disease).
Data on the patients’ characteristics were retrieved by the four 
investigators from a computerized database concerning the ICU 
stay. The following data were collected on ICU admission: demo-
graphics (age and sex); etiology; arterial blood gas (pH, bicarbon-
ate, and lactate) and arterial laboratory (INR, factor V, alanine 
transferase, bilirubin, ammonia, creatinine, phosphorus, and lac-
tate) results; grade of HE (West Haven criteria); requirement for 
organ support (invasive mechanical ventilation [IMV], vasopres-
sors, renal replacement therapy [RRT]); and fulfilment of the 
KCC.
The primary outcome was all-cause hospital mortality. The sec-
ondary outcomes were all-cause 90-day mortality following ICU 
admission, LT during hospital stay, and ICU and hospital length 
of stay.
Statistical Analysis
Baseline characteristics are described as number (%) for cate-
gorical variables and median (interquartile range [IQR]) for con-
tinuous variables. There were 4.8% missing values across variables, 
thus no imputation was done.
Associations of baseline characteristics with the primary end-
point were assessed using univariate logistic regression. The dis-
criminative ability of the KCC for LT was studied using the AUC 
(area under the receiver operating curve).
Statistical significance was set at p < 0.05. The statistical analy-
sis was performed using SPSS version 20.0 (IBM Corp., Armonk, 
NY, USA).
Results
Baseline Characteristics and Outcomes
During the ICU stay, 34 patients were diagnosed with 
ALF (30 on ICU admission) and 15 patients had ALI 
(Fig. 1).
Amongst all patients with ALF (n = 34), the median 
age (IQR) was 49 (31–67) years, and 21 (62%) were fe-
males. Non-paracetamol etiologies were found in 29 pa-
tients (85%). The ALF etiologies are specified in Figure 2.
On ICU admission, grade 3–4 HE developed in 10 pa-
tients (29%), and the median arterial ammonia level was 
152 (93–197) μmol/L. At the same time point, the me-
dian arterial INR and bilirubin, creatinine, bicarbonate, 
and lactate levels were 3.0 (2.2–6.3), 9.8 (3.4–19.7) mg/
dL, 1.4 (0.6–2.0) mg/dL, 20 (16–24) mmol/L, and 3.3 
(1.9–8.0) mmol/L, respectively. Also on ICU admission, 
IMV, vasopressors, and RRT were required in 8 (24%), 7 
(21%), and 5 patients (15%), respectively. At the same 













Vascular Virus Ischemia Other UnknownDILI Para-
cetamol
n
Fig. 2. Etiologies of acute liver failure 
amongst patients admitted to the intensive 
care unit (n = 34). DILI, drug-induced liver 
injury.
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All patients’ characteristics on ICU admission are shown 
in Table 1.
Of all patients with ALF (n = 34), 15 (44%) died during 
their hospital stay (11 without LT). Following exclusion 
of 3 foreign patients lost to follow-up (n = 31), 15 (48%) 
died within 90 days following ICU admission. During 
their hospital stay, 19 patients (56%) underwent trans-
plantation. LT was significantly associated with lower 
hospital mortality (21 vs. 73%; p = 0.005). The outcomes 
and causes of death are detailed in Table 2 and Figure 3, 
respectively.
Of all the baseline characteristics, age (unadjusted 
odds ratio [uOR] = 1.04 per year increment), creatinine 
(uOR = 3.36 per unit increment), and bicarbonate 
(uOR = 0.80 per unit increment) were significantly asso-
ciated with hospital mortality (Table 1).
Patients Undergoing Transplantation
Amongst the patients with ALF who underwent LT 
during their hospital stay (n = 19), the median age (IQR) 
was 44 (32–57) years, and 12 (63%) were female. Non-
paracetamol etiologies were found in 18 patients (95%).
On ICU admission, grade 3–4 HE developed in 5 pa-
tients (26%), and the median arterial ammonia level was 
157 (77–224) μmol/L. At the same time point, the median 
arterial INR, bilirubin, creatinine, bicarbonate, and lac-
tate levels were 3.4 (2.4–7.0), 15.2 (3.8–21.0) mg/dL, 0.7 
(0.5–1.5) mg/dL, 23 (19–25) mmol/L, and 2.8 (1.8–6.8) 
Table 1. Baseline characteristics of the patients with acute liver 
failure admitted to the intensive care unit (n = 34)
Age, years 49 (31–67)1
Female sex 21 (62%)
Non-paracetamol etiology 29 (85%)
Grade 3–4 hepatic encephalopathy 10 (29%)
Ammonia, µmol/L 152 (93–197)
INR 3.0 (2.2–6.3)
Factor V, % 22 (14–46)
Bilirubin, mg/dL 9.8 (3.4–19.7)
ALT, U/L 1,957 (341–5,884)
Invasive mechanical ventilation 8 (24%)
PF ratio, mm Hg 340 (288–433)
Vasopressor support 7 (21%)
Mean arterial pressure, mm Hg 77 (66–88)
Renal replacement therapy 5 (15%)
Creatinine, mg/dL (n = 33) 1.4 (0.6–2.0)2
pH (n = 31) 7.40 (7.33–7.47)
Bicarbonate, mmol/L (n = 31) 20 (16–24)3
Potassium, mmol/L 4.1 (3.8–4.7)
Phosphorus, mg/dL (n = 31) 3.2 (2.6–4.7)
Lactate, mmol/L (n = 31) 3.3 (1.9–8.0)
KCC 16 (47%)
Values are presented as n (%) or median (interquartile range). 
ALT, alanine aminotransferase; PF ratio, oxygen arterial pressure/
oxygen inspiration fraction; KCC, King’s College criteria; OR, 
odds ratio; 95% CI, 95% confidence interval. 1 OR (95% CI) for 
hospital mortality: 1.04 (1.00–1.09); p = 0.039. 2 OR (95% CI) for 
hospital mortality: 3.36 (1.14–9.92); p = 0.028. 3 OR (95% CI) for 
hospital mortality: 0.80 (0.67–0.85); p = 0.012.
Table 2. Outcomes of the patients with acute liver failure admitted 
to the intensive care unit (n = 34)
Intensive care unit stay, days 3 (6–11)
Hospital stay, days 24 (10–36)
Liver transplant during hospital stay 19 (56%)
Time to liver transplant, days 3 (1–6)
Mortality during hospital stay 15 (44%)
Mortality within 90 days1 15 (48%)
Time to death, days 4 (2–7)
Follow-up1, days 229 (4–405)
Values are presented as n (%) or median (interquartile range). 
1 Excluding 3 cases lost to follow-up after hospital discharge (n = 31).
Table 3. Baseline characteristics of the patients with acute liver 
failure admitted to the intensive care unit who underwent liver 
transplantation (n = 19)
Age, years 44 (32–57)
Female sex 12 (63%)
Non-paracetamol etiology 18 (95%)
Grade 3–4 hepatic encephalopathy 5 (26%)
Ammonia, µmol/L 157 (77–224)
INR 3.4 (2.4–7.0)
Factor V, % 38 (9–50)
Bilirubin, mg/dL 15.2 (3.8–21.0)
ALT, U/L 1,904 (768–5,868)
Invasive mechanical ventilation 3 (15%)
PF ratio, mm Hg 393 (295–433)
Vasopressor support 2 (11%)
Mean arterial pressure, mm Hg 78 (67–87)
Renal replacement therapy 2 (11%)
Creatinine, mg/dL (n = 18) 0.7 (0.5–1.5)
pH (n = 16) 7.42 (7.37–7.48)
Bicarbonate, mmol/L (n = 16) 23 (19–25)
Potassium, mmol/L 4.1 (3.8–4.3)
Phosphorus, mg/dL (n = 18) 2.9 (2.6–4.1)
Lactate, mmol/L (n = 16) 2.8 (1.8–6.8)
KCC 13 (68%)
Values are presented as n (%) or median (interquartile range). 
ALT, alanine transferase; PF ratio, oxygen arterial pressure/oxygen 
inspiration fraction; KCC, King’s College criteria.
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mmol/L, respectively. Also on ICU admission, IMV, va-
sopressors, and RRT were required in 3 (15%), 2 (11%), 
and 2 patients (11%), respectively. At the same time point, 
the KCC were fulfilled by 13 patients (68%). All trans-
planted patients’ characteristics on ICU admission are 
shown in Table 3.
Of the patients fulfilling the KCC on ICU admission 
(n = 16), 13 (81%) effectively underwent transplantation 
during their hospital stay; the 3 remaining patients died 
during their hospital stay. While the KCC were not asso-
ciated with hospital mortality (p = 0.97), they were sig-
nificantly associated with LT during the hospital stay 
(p = 0.008) (sensitivity 68%, specificity 80%, negative pre-
dictive value 67%, and positive predictive value 81%; 
AUC [95% confidence interval] = 0.74 [0.57–0.91]).
Discussion
Key Findings
In Lisbon, Portugal, the ICU at the local LT center ad-
mitted about 10 patients per year with ALF between Oc-
tober 2013 and December 2016. Non-paracetamol etiolo-
gies represented 85% of all the ALF cases.
The all-cause mortality rates during the hospital stay 
and 90 days following ICU admission were 44% (73% 
without LT and 21% following LT) and 48%, respectively. 
LT was performed on 56% of the patients.
Older age, renal dysfunction (creatinine), and meta-
bolic imbalance (bicarbonate) on ICU admission were 
significantly associated with worse hospital mortality 
rate. The KCC were not associated with hospital mortal-
ity, but they were significantly associated with the deci-
sion for LT during the hospital stay.
Comparison with the Previous Literature
The vast majority of ALF cases in our cohort (85%) 
were not paracetamol related. This finding is in agree-
ment with some reports on ALF epidemiology from con-
tinental Europe. In a multicenter study from Germany 
(2008–2009), non-paracetamol etiologies accounted for 
91% of all ALF cases [7]. Conversely, in the UK, para-
cetamol-related ALF may represent about 65% of all cas-
es [3]. This issue has largely to do with cultural differ-
ences regarding the public use of paracetamol; in the UK 
this has been associated with suicide attempts [13]. In 
Portugal, this phenomenon does not have the same rele-
vance in terms of public health.
The all-cause mortality rate during the hospital stay in 
our cohort was 73% without LT and 21% following LT. 
In the German cohort mentioned above [7], the all-cause 
mortality rate during the hospital stay was 35% without 
LT and 20% following LT. While it has been established 
that patients with non-paracetamol-related ALF have a 
worse prognosis than those with paracetamol overdos-
age, both our and the German cohort predominantly had 
non-paracetamol etiologies; therefore, they likely includ-
ed more of the subgroup of patients with ALF at the high-
est risk of death. Nevertheless, the mortality amongst the 
transplant-free patients in our cohort (73%) was greater 
than in the German cohort (35%). This difference may to 
some extent be related to the fact that the following ALF 
severity markers were more frequently worse in our co-





















Fig. 3. Causes of death amongst patients 
with acute liver failure admitted to the in-
tensive care unit (n = 34).
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years), INR (3.0 vs. 2.5), creatinine (1.4 vs. 1.0 mg/dL) 
and lactate (3.3 vs. 3.0 mmol/L) levels, and the propor-
tion of patients fulfilling the KCC on ICU admission (47 
vs. 37%) [1]. However, we need to improve the diagnos-
tic and treatment strategies for patients with non-
paracetamol-related ALF without LT. Such steps may in-
clude the following aspects: earlier referral to the local LT 
center, N-acetylcysteine use especially for low-grade HE 
patients, more aggressive organ support in the ICU, and 
frequent sepsis screening and timely antimicrobial treat-
ment [1].
In our cohort, 56% of the patients with ALF underwent 
transplantation. This rate is similar to the one found in a 
Spanish multicenter cohort (56%) [14]. The posttrans-
plant mortality rates were similar in our (21%) and the 
German (20%) cohort. The selection criteria for LT in this 
context seem to have affected patient outcomes similarly 
in these cohorts. Nevertheless, use of the KCC did not 
show any association with hospital mortality in our co-
hort. In fact, the KCC have been shown to lack good sen-
sitivity (58%) for predicting hospital mortality from non-
paracetamol-related ALF [15, 16]. Furthermore, while 
these patients benefit more from LT than do patients with 
paracetamol overdosage, the likelihood of death is much 
higher if an organ is not timely available or if there are 
contraindications to LT (e.g., ongoing sepsis, psychiatric 
disorder, and malignancy).
Limitations
This study has to be considered in the context of the 
following limitations: (1) its retrospective character car-
ries the risk of selection bias and (2) the low number of 
patients included may influence the internal and external 
validity of our findings.
To mitigate the risk of selection bias, we selected con-
secutive patients with ALF based on specific criteria ac-
cepted worldwide. Given that ALF is a rare disease, the 
number of patients included in a country such as Portugal 
may in fact be reasonable. To enforce the internal validity 
of our findings, we used a data set with a low level of miss-
ing data (< 5%).
In order to further study the epidemiology of ALF in 
Portugal, we should aim to combine data from the three 
LT regions in the country. For that, a fully functioning 
prospective registry would be of great interest. This kind 
of measure would surely help to improve the quality of 
care provided to these patients nationwide.
Conclusions
In a southern Portuguese cohort of patients with ALF, 
non-paracetamol etiologies were predominant. Hospital 
mortality was much lower amongst LT patients.
Acknowledgments
Thanks are due to the Intensive Care Unit and Liver Transplant 
Program personnel at Curry Cabral Hospital for their collabora-
tion.
Statement of Ethics
Given the observational character of the study, the local ethics 
committee waived the need for individual informed consent. The 
principles of the Declaration of Helsinki were respected through-
out study development.
Disclosure Statement
The authors have no conflicts of interest to report.
Author Contributions
C.S., S.M., and M.V. helped to collect data and draft the manu-
script. F.S.C. developed the idea, helped to collect data, performed 
the statistical analysis, and finalized the manuscript.
References  1 Cardoso FS, Marcelino P, Bagulho L, Karvel-
las CJ: Acute liver failure: an up-to-date ap-
proach. J Crit Care 2017; 39: 25–30.
 2 Germani G, Theocharidou E, Adam R, Karam 
V, Wendon J, O’Grady J, et al: Liver trans-
plantation for acute liver failure in Europe: 
outcomes over 20 years from the ELTR data-
base. J Hepatol 2012; 57: 288–296.
 3 Bernal W, Hyyrylainen A, Gera A, Audimo-
olam VK, McPhail MJ, Auzinger G, et al: Les-
sons from look-back in acute liver failure? A 
single centre experience of 3,300 patients. J 
Hepatol 2013; 59: 74–80.
 4 Acharya SK, Batra Y, Hazari S, Choudhury V, 
Panda SK, Dattagupta S: Etiopathogenesis of 
acute hepatic failure: Eastern versus Western 
countries. J Gastroenterol Hepatol 2002; 17 
(suppl 3):S268–S273.
Epidemiology of Acute Liver Failure 39GE Port J Gastroenterol 2019;26:33–39
DOI: 10.1159/000487312
 5 Ostapowicz G, Fontana RJ, Schiødt FV, Lar-
son A, Davern TJ, Han SH, et al: Results of a 
prospective study of acute liver failure at 17 
tertiary care centers in the United States. Ann 
Intern Med 2002; 137: 947–954.
 6 Gulmez SE, Larrey D, Pageaux GP, Bernuau J, 
Bissoli F, Horsmans Y, et al: Liver transplant 
associated with paracetamol overdose: results 
from the seven-country SALT study. Br J Clin 
Pharmacol 2015; 80: 599–606.
 7 Hadem J, Tacke F, Bruns T, Langgartner J, 
Strnad P, Denk GU, et al: Etiologies and out-
comes of acute liver failure in Germany. Clin 
Gastroenterol Hepatol 2012; 10: 664–669.e2.
 8 Areia M, Romãozinho JM, Ferreira M, Amaro 
P, Leitão MC: Fulminant hepatic failure: a 
Portuguese experience. Eur J Gastroenterol 
Hepatol 2007; 19: 665–669.
 9 Fontana RJ, Ellerbe C, Durkalski VE, Rang-
nekar A, Reddy RK, Stravitz T, et al: Two-year 
outcomes in initial survivors with acute liver 
failure: results from a prospective, multicen-
tre study. Liver Int 2015; 35: 370–380.
10 World Medical Association: World Medical 
Association Declaration of Helsinki: ethical 
principles for medical research involving hu-
man subjects. JAMA 2013; 310: 2191–2194.
11 Bernal W, Hall C, Karvellas CJ, Auzinger G, 
Sizer E, Wendon J: Arterial ammonia and 
clinical risk factors for encephalopathy and 
intracranial hypertension in acute liver fail-
ure. Hepatology 2007; 46: 1844–1852.
12 O’Grady J: Timing and benefit of liver trans-
plantation in acute liver failure. J Hepatol 
2014; 60: 663–670.
13 Hawton K, Bergen H, Simkin S, Dodd S, Po-
cock P, Bernal W, et al: Long term effect of 
reduced pack sizes of paracetamol on poison-
ing deaths and liver transplant activity in Eng-
land and Wales: interrupted time series analy-
ses. BMJ 2013; 346:f403.
14 Escorsell A, Mas A, de la Mata M; Spanish 
Group for the Study of Acute Liver Failure: 
Acute liver failure in Spain: analysis of 267 
cases. Liver Transpl 2007; 13: 1389–1395.
15 McPhail MJ, Farne H, Senvar N, Wendon JA, 
Bernal W: Ability of King’s College criteria 
and model for end-stage liver disease scores to 
predict mortality of patients with acute liver 
failure: a meta-analysis. Clin Gastroenterol 
Hepatol 2016; 14: 516–525.e5; quiz e43–e45.
16 Craig DGN, Ford AC, Hayes PC, Simpson KJ: 
Systematic review: prognostic tests of 
paracetamol-induced acute liver failure. Ali-
ment Pharmacol Ther 2010; 31: 1064–1076.
